McKesson (NYSE:MCK) Stock Price Expected to Rise, Mizuho Analyst Says

McKesson (NYSE:MCK) had its target price hoisted by Mizuho from $880.00 to $885.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Mizuho’s price target suggests a potential downside of 6.64% from the company’s previous close.

A number of other analysts have also commented on the stock. Barclays initiated coverage on shares of McKesson in a research note on Monday, December 8th. They issued an “overweight” rating and a $960.00 price target for the company. Evercore reiterated an “outperform” rating and set a $1,000.00 target price on shares of McKesson in a research note on Thursday, November 6th. TD Cowen lifted their price objective on McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company increased their target price on McKesson from $816.00 to $914.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Finally, Weiss Ratings restated a “buy (a-)” rating on shares of McKesson in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $918.93.

McKesson Stock Down 1.0%

Shares of MCK opened at $947.96 on Thursday. McKesson has a twelve month low of $583.55 and a twelve month high of $971.93. The company has a market capitalization of $116.12 billion, a P/E ratio of 27.26, a price-to-earnings-growth ratio of 1.56 and a beta of 0.40. The firm has a 50 day moving average of $828.41 and a 200 day moving average of $779.58.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, sell-side analysts expect that McKesson will post 32.77 EPS for the current year.

Insider Activity

In related news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the sale, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.08% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MCK. GGM Financials LLC purchased a new position in shares of McKesson in the 3rd quarter worth $25,000. Solstein Capital LLC grew its position in McKesson by 171.4% in the second quarter. Solstein Capital LLC now owns 38 shares of the company’s stock worth $28,000 after acquiring an additional 24 shares in the last quarter. State of Wyoming bought a new stake in McKesson during the second quarter worth approximately $29,000. GFG Capital LLC purchased a new stake in McKesson during the second quarter valued at approximately $30,000. Finally, Hopwood Financial Services Inc. bought a new stake in shares of McKesson in the 3rd quarter valued at approximately $31,000. 85.07% of the stock is currently owned by institutional investors.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results beat consensus: EPS topped estimates and revenue grew ~11.4% year‑over‑year; management raised FY‑2026 adjusted EPS guidance to $38.80–$39.20, underpinning today’s rally. McKesson Q3 Earnings Call Highlights
• Positive Sentiment: Growth drivers called out on the call: oncology, specialty distribution and technology businesses accelerated, which McKesson cites as the basis for the raised profit outlook. MCK Q3 Earnings & Sales Top Estimates, 2026 View Up
• Positive Sentiment: Strong market reaction: analysts and investors pushed the share price sharply higher on the beat + guidance, citing the bigger‑than‑expected lift to FY26 adjusted EPS. How McKesson Stock Surged 17% In A Day
• Neutral Sentiment: Analyst target changes mixed: some firms raised price targets (e.g., Wells Fargo, Mizuho) but ratings stayed neutral/equal‑weight, leaving upside expectations varied among brokers. Price Target Raised to $925.00 at Wells Fargo & Company
• Neutral Sentiment: Company materials and transcripts are available for detailed review (presentation and full earnings call transcript) — useful for checking segment KPIs, margin drivers and guidance assumptions. Q3 2026 earnings call transcript
• Negative Sentiment: Operational cash flow weakness flagged: some reports note weaker operating cash flow despite profit growth, and balance‑sheet metrics (higher liabilities) warrant watching for sustainability of buybacks/dividends. EPS Beats, Profit Growth but Weak Operating Cash Flow
• Negative Sentiment: Insider selling is noted in recent filings; combined with high share price momentum, this can contribute to near‑term volatility or profit‑taking. Insider Trading and Hedge Fund Activity

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.